A mechanism‐based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID‐19 treatment in humans
Abstract The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) outbreak initiated the global coronavirus disease 2019 (COVID‐19) pandemic resulting in 42.9 million confirmed infections and > 1.1 million deaths worldwide as of October 26, 2020. Remdesivir is a broad‐spectrum nucleotide...
Saved in:
Main Authors: | Patrick O. Hanafin (Author), Brian Jermain (Author), Anthony J. Hickey (Author), Alexander V. Kabanov (Author), Angela DM. Kashuba (Author), Timothy P. Sheahan (Author), Gauri G. Rao (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions
by: Subrata Deb, et al.
Published: (2021) -
The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance
by: Daisy Yan, et al.
Published: (2021) -
Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation
by: Mohamed Aborig, et al.
Published: (2019) -
The role of studies of interspecies differences pharmacokinetics in the creation of new peptide drugs
by: V. P. Zherdev, et al.
Published: (2018) -
Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin
by: Simona Catozzi, et al.
Published: (2023)